# Vaxart, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Vaxart, Inc.). ## Overview Vaxart, Inc. is a U.S.-based clinical-stage biotechnology company focused on developing oral recombinant vaccines using its proprietary VAAST platform. Its pipeline includes prophylactic vaccine candidates for infectious diseases such as norovirus, coronavirus, and influenza, as well as a therapeutic HPV vaccine candidate in preclinical development. ## Products & services • Oral recombinant vaccine platform (VAAST) • Norovirus prophylactic vaccine candidate • Oral coronavirus/COVID-19 vaccine candidate • Oral influenza vaccine candidate • HPV therapeutic vaccine candidate • Government-funded vaccine development programs - **Oral vaccine platform** (0%) — Proprietary tablet-based vaccine technology designed to stimulate mucosal, systemic, and T-cell responses. - **Infectious disease vaccine candidates** (0%) — Prophylactic vaccine programs targeting norovirus, coronavirus, and influenza. - **Therapeutic vaccine candidates** (0%) — Preclinical vaccine programs aimed at HPV-related cervical cancer and dysplasia. - **Government contract revenue** (94%) — Revenue from U.S. government-funded development contracts supporting vaccine programs. - **Royalty and collaboration revenue** (6%) — Non-cash royalty revenue and license/collaboration income tied to partnered assets. - Oral recombinant vaccine platform (VAAST) - Norovirus prophylactic vaccine candidate - Oral coronavirus/COVID-19 vaccine candidate - Oral influenza vaccine candidate - HPV therapeutic vaccine candidate - Government-funded vaccine development programs ## Customers Vaxart’s direct customers are primarily government agencies and contract counterparties that fund vaccine research and development programs. If its candidates are commercialized, the end customers would be public health systems, healthcare providers, and potentially international commercial partners that distribute vaccines in their markets. - **U.S. government agencies** (primary) — Fund clinical and development work through government contracts for vaccine candidates. - **Collaborative development partners** (primary) — Partner with Vaxart on development, funding, and future commercialization rights. - **Future vaccine purchasers** (secondary) — Healthcare systems, public health programs, and distributors that would buy approved vaccines. - **Royalty payors and license counterparties** (secondary) — Third parties tied to legacy partnered assets that generate royalty or license revenue. - U.S. government agencies funding vaccine development contracts - Collaborative partners supporting development and commercialization - Public health buyers for infectious disease prevention products - International distributors or licensees for ex-U.S. markets - Royalty counterparties tied to partnered influenza assets ## Geography Vaxart is headquartered in the United States and conducts its core research, development, and contracting activities from there. Its business is centered on U.S.-based government programs today, while future commercialization of tablet vaccines could extend into international markets through collaborators or licensees. - Headquartered in the United States - Core R&D and clinical contracting are U.S.-based - Government contract revenue is primarily tied to U.S. agencies - Future commercialization may rely on ex-U.S. collaborators - International markets matter for eventual vaccine rollout ## Strategy Vaxart’s strategy centers on advancing its oral vaccine platform through clinical development, government-funded programs, and selective collaborations. The company also seeks to preserve optionality for future commercialization by using partners for certain markets while retaining rights where possible. - **Advance oral vaccine candidates through development** (medium-term) — Clinical progress is the main path to validating the platform and creating future product value. - **Secure external funding and partnerships** (short-term) — Government contracts and collaborations reduce funding burden and support ongoing R&D. - **Protect and extend intellectual property** (long-term) — Patent and regulatory exclusivity are central to monetizing a platform-based biotech business. - Advance the VAAST oral vaccine platform through clinical trials - Use government contracts to fund development work - Pursue collaborations for ex-U.S. commercialization - Develop infectious disease and HPV vaccine programs - Protect platform value through patents and know-how ## Risks Vaxart faces the typical risks of a clinical-stage biotech company: uncertain clinical outcomes, dependence on third-party manufacturers and research vendors, and a need for ongoing external capital. Its business is also exposed to contract concentration, regulatory and commercialization risk, and reduced trading liquidity after Nasdaq delisting. - **Clinical development and regulatory failure** [high] — Vaccine candidates must succeed in trials and obtain approval before generating product revenue. - **Third-party manufacturing and clinical service dependence** [high] — The company relies on external CROs, labs, and contract manufacturers for development work. - **Funding and liquidity risk** [critical] — The business requires continued capital raises and/or partner funding to sustain R&D. - **Government contract concentration** [high] — A large share of revenue is tied to a small number of government contracts that can be stopped or reprioritized. - **Trading liquidity and capital markets access** [medium] — Delisting from Nasdaq can reduce liquidity and make future financing more difficult. - Clinical trial failure could prevent product approval - Dependence on third-party manufacturers can disrupt supply - Government contract funding can stop or be reduced - Additional capital may be needed to continue operations - OTCQX trading and delisting reduce financing flexibility ## Accounting The most important accounting judgments for Vaxart relate to revenue recognition on government contracts, which can be recognized over time as work is performed and may change with contract scope or stop-work notices. Investors should also watch accrued R&D expenses, royalty accounting under the HCRP arrangement, and estimates tied to clinical services and contract manufacturing obligations. - **Government contract revenue recognition** — Can create large quarter-to-quarter swings in reported revenue - **Accrued research and development expenses** — Affects operating expenses and liabilities - **Royalty revenue and HCRP waterfall** — Affects other revenue and cash conversion - **Purchase commitments** — Impacts liquidity analysis and balance sheet obligations - Government contract revenue depends on progress and contract terms - Stop-work or scope changes can shift revenue timing materially - Accrued R&D estimates reflect unbilled CRO and manufacturing work - Royalty revenue is affected by the HCRP payment waterfall - Purchase commitments and clinical accruals affect near-term liabilities --- *Last updated: 2026-04-29T05:07:28.802600+00:00*